Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.

British journal of clinical pharmacology - 1 Dec 2010

Helsby Nuala A, Hui Chung-Yee, Goldthorpe Michael A, Coller Janet K, Soh May Ching, Gow Peter J, De Zoysa Janak Z, Tingle Malcolm D

Abstract excerpt

AIMS: The role of CYP pharmacogenetics in the bioactivation of cyclophosphamide is still controversial. Recent clinical studies have suggested a role for either CYP2C19 or CYP2B6. The aim of this study was to clarify the role of these pharmacogenes. METHODS: We used a combined in vitro-in vivo ap...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophosphamide
Share to Cytochrome P-450 CYP2B6
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Lupus Nephritis

Share to Microsomes, Liver

Share to Oxidoreductases, N-Demethylating

Share to Tissue Banks

Source

Open in PubMed Open full text

Identifiers

PMID: 21175440
DOI: 10.1111/j.1365-2125.2010.03789.x
PMCID: PMC3014068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21175440-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.PMID 21175440Read ↗

Cyclophosphamide pharmacogenomics and their effect on its bioactivation and pharmacokineticsSemantic proximity Read ↗

Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.Semantic proximity Read ↗

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.Semantic proximity Read ↗

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesSemantic proximity Read ↗

Exploring the Correlation Between Genotypes of Drug-Metabolizing Enzymes and the Therapeutic Efficacy and Adverse Reactions of Cyclophosphamide in Childhood-Onset Lupus Nephritis: A Chinese Cohort Study.Semantic proximity Read ↗

Association of ALDH1A1 Polymorphism With Toxicity From Cyclophosphamide TreatmentSemantic proximity Read ↗

Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.Semantic proximity Read ↗

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.Semantic proximity Read ↗

Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy.Semantic proximity Read ↗

Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.Semantic proximity Read ↗

Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.Semantic proximity Read ↗

Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.